Promoter (4G/5G) plasminogen activator inhibitor-1 genotype in Pima Indians: Relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndrome

Diabetologia

Volumn 39, Issue 12, 1996, Pages 1512-1518

  McCormack, L J ^a,e   Nagi, D K ^b   Stickland, M H ^a   Mansfield, M W ^a   Mohamed Ali, V ^c   Yudkin, J S ^c   Knowler, W C ^d   Grant, P J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b Edna Coates Diabetes Centre   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

diabetes mellitus; fibrinolysis; genetic; non insulin dependent; Pima Indians; plasminogen activator inhibitor 1; polymorphism

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INDIAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

EID: 0029972253     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050606     Document Type: Article

References (51)

1. Kannel WB, McGee DL (1979) Diabetes and cardiovascular disease, the Framingham Study. JAMA 241: 2035-2038
2. Multiple Risk Factor Intervention Trial (MRFIT) Research Group (1982) Multiple risk factor intervention trial: risk factor changes and mortality results. JAMA 248: 1465-1477
3. Pyörälä K (1979) Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease. Results from two population studies in Finland. Diabetes Care 2:131-141
4. Walmsley D, Hampton KK, Grant PJ (1991) Contrasting fibrinolytic responses in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes. Diabet Med 8: 954-959
5. Auwerx J, Bouillon R, Collen D, Geboers J (1988) Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 8: 68-72
6. Garcia Frade LJ, de la Calle H, Torrado MC, Lara JI, Cuellar L, Garcia Avello A (1990) Hypofibrinolysis associated with vasculopathy in non insulin dependent diabetes mellitus. Thromb Res 59: 51-59
7. Gough SCL, Rice PJS, McCormack L, Chapman C, Grant PJ (1993) The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus. Diabet Med 10: 638-642
8. Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P (1989) Increased plasminogen activator inhibitor activity in non-insulin-dependent diabetic patients - relationship with plasma insulin. Thromb Haemost 61: 370-373
9. Smith EB (1986) Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis. Clin Haematol 15: 355-370
10. Dawson S, Hamsten A, Wiman B, Henney A, Humphries S (1991) Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb 11: 183-190
11. Dawson S, Wiman B, Hamsten A, Green F, Humphries S, Henney A (1993) The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 268: 10739-10745
12. Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries S, Yudkin J (1995) Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 44: 37-42
13. Eriksson P, Kallin B, van 'T Hooft FM, Båvenholm P, Hamsten A (1995) Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 92: 1851-1855
14. Ye S, Green FR, Scarabin PY et al. (1995) The 4G/5G genetic polymorphism in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-I activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 74: 837-841
15. Mansfield MW, Stickland MH, Grant PJ (1995) Environmental and genetic factors in relation to circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 74: 842-847
16. Bennett PH, Rushforth NB, Miller M, LeCompte PM (1976) Epidemiologie studies of diabetes in the Pima Indians. Recent Prog Horm Res 32: 333-376
17. Knowler WC, Bennett PH, Hamman RF, Miller M (1978) Diabetes incidence and prevalence in Pima Indians: a 19-fold greater incidence than in Rochester, Minnesota. Am J Epidemiol 108:497-505
18. Knowler WC, Pettitt DJ, Savage PJ, Bennett PH (1981) Diabetes incidence in Pima Indians: contribution of obesity and parental diabetes. Am J Epidemiol 113: 144-156
19. Nelson RG, Sievers ML, Knowler WC et al. (1990) Low incidence of fatal coronary heart disease in Pima Indians despite high prevalence of non-insulin-dependent diabetes. Circulation 81: 987-995
20. Howard BV, Welty TK, Fabsitz RR et al. (1992) Risk factors for coronary heart disease in diabetic and non-diabetic native Americans. The Strong Heart Study. Diabetes 41 [Suppl 2]:4-11
21. Sievers ML, Nelson RG, Bennett PH (1990) Adverse mortality experience of a southwestern American Indian community: overall death rates and underlying causes of death in Pima Indians. J Clin Epidemiol 43: 1231-1242
22. Nagi DK, Knowler WC, Hanson RL, Mohamed Ali V, Yudkin JS (1996) Plasminogen activator inhibitor-1 (PAI-1) and non-insulin-dependent diabetes in Pima Indians. South Asians and Europeans: populations at varying risk of NIDDM and coronary artery disease. Thromb Haemost 75: 921-927
23. World Health Organisation (1985) Diabetes mellitus. Report of a WHO Study Group. Technical Report Series No. 727, WHO, Geneva
24. Sobey WJ, Beer SF, Carrington CA et al. (1989) Sensitive and specific two-site immunoradiometric assays to human insulin, proinsulin, 65-66 split and 32-33 split proinsulin. Biochem J 260: 535-541
25. Mohamed-Ali V, Yudkin JS (1992) An end-point amplified immunoenzymometric assay (IEMA) specific for human insulin. Clin Sci 82:[Suppl 27] 4P (Abstract)
26. Falk G, Almqvist A, Nordenhem A, Svensson H, Wiman B (1995) Allele specific PCR for detection of a sequence polymorphism in the promoter region of the plasminogen activator inhibitor-1 (PAI-1) gene. Fibrinolysis 9: 170-174
27. Armitage P, Berry G (1987) Statistical methods in medical research. 2nd edn Blackwell, Oxford, UK. pp 273-282
28. Hamsten A, Wiman B, de Faire U, Blombäck M (1985) Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 313: 1557-1563
29. Hamsten A, de Faire U, Walldius G et al. (1987) Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2: 3-9
30. Gray RP, Yudkin JS, Patterson DL (1993) Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction - A role for plasminogen activator inhibitor? Br Heart J 70: 530-536
31. Landin K, Tengborn L, Smith U (1990) Elevated fibrinogen and plasminogen activator inhibitors (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Int Med 227: 273-278
32. Landin K, Stigendal L, Eriksson E et al. (1990) Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 39: 1044-1048
33. Potter van Loon BJ, Kluft K, Radder JK, Blankenstein MA, Meinders AE (1993) The cardiovascular risk factor plasminogen activator inhibitor-1 is related to insulin resistance. Metabolism 42: 945-949
34. Vague P, Juhan-Vague I, Aillaud MF et al. (1986) Correlation between blood fibrinolytic activity, plasminogen activator inhibitor level, plasma insulin level, and relative body weight in normal and obese subjects. Metabolism 35: 250-253
35. Juhan-Vague I, Alessi MC, Joly P et al. ( 1989) Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute phase-response. Arteriosclerosis 9: 362-367
36. Sundell IB, Nilsson TK, Hallmans G, Hellsten G, Dahlen GH (1989) Interrelationships between plasma levels of plasminogen activator inhibitor, tissue plasminogen activator, lipoprotein(a), and established cardiovascular risk factors in a North Swedish population. Atherosclerosis 80: 9-16
37. Mussoni L, Mannucci L, Sirtori M et al. (1992) Hypertriglyceridaemia and regulation of fibrinolytic activity. Arterioscler Thromb 12: 19-27
38. Mehta J, Mehta P, Lawson D, Saldeen T (1987) Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlations with age and triglyceride concentrations. J Am Coll Cardiol 9: 263-268
39. Alessi MC, Juhan-Vague I, Kooistra T, Declerk PJ, Collen D (1988) Insulin stimulates the synthesis of plasminogen activator-1 by hepatocellular cell line Hep G2. Thromb Haemost 60: 491-494
40. Kooistra T, Bosma PJ, Tons HAM, van den Berg AP, Meyer P, Princen HMG (1989) Plasminogen activator inhibitor 1: biosynthesis and mRNA level are increased in Hep G2 cells. Thromb Haemost 62: 723-728
41. Grant PJ, Rüegg M, Medcalf RL (1991) Basal expression and insulin-mediated induction of PAI-1 mRNA in Hep G2 cells. Fibrinolysis 5: 81-86
42. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J (1990) Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. Arteriosclerosis 10: 1067-1073
43. Maiello M, Boeri D, Podesta F et al. (1992) Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose. Diabetes 41: 1009-1015
44. Nordt TK, Klassen KJ, Schneider DJ, Sobel BE (1993) Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb 13: 1822-1828
45. Grant PJ, Kruithof EKO, Felley CP, Felber JP, Bachmann F (1990) Short term infusions of insulin, triacylglycerol and glucose do not cause acute increases in plasminogen activator inhibitor-1 concentrations in man. Clin Sci 79: 513-516
46. Potter van Loon BJ, deBart ACW, Radder JK, Freilich M, Kluft C, Meinders AE (1990) Acute exogenous hyperinsulinaemia does not result in elevation of plasminogen activator inhibitor-1 (PAI-1) in humans. Fibrinolysis 4 [Suppl 2]:93-94
47. Landin K, Tengborn L, Chmielewska J, von Schenck H, Smith U (1991) The acute effect of insulin on tissue plasminogen activator and plasminogen activator inhibitor in man. Thromb Haemost 65: 130-133
48. McCormack L, Stickland MH, Grant PJ (1993) Plasminogen activator inhibitor-1 antigen concentrations during insulin and oral glucose tolerance tests in obese man. Fibrinolysis 7: 225-228
49. Gunnarsson R, Nyman D, Wålinder O, Östman J (1980) Fibrinolytic activity and diabetes control - evidence for a relationship. A preliminary report. Acta Med Scand [Suppl] 639: 23-24
50. van Wersch JWJ, Donders SHJ, Westerhuis LWJJM, Venekamp WJRR (1991) Microalbuminuria in diabetic patients: relationship to lipid glyco-metabolic, coagulation and fibrinolysis parameters. Eur J Clin Chem Clin Biochem 29: 493-498
51. Mansfield MW, Stickland MH, Grant PJ (1995) Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in non insulin dependent diabetes. Thromb Haemost 74: 1032-1034